These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35153149)

  • 1. Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.
    Thoi F; Scherer DJ; Kaye DM; Sanders P; Stokes MB
    Heart Lung Circ; 2022 May; 31(5):616-622. PubMed ID: 35153149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methamphetamine-associated cardiomyopathy: an addiction medicine perspective.
    Somma V; Osekowski M; Paratz E; Bonomo Y
    Intern Med J; 2023 Jan; 53(1):21-26. PubMed ID: 36693638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review.
    Reddy PKV; Ng TMH; Oh EE; Moady G; Elkayam U
    J Am Heart Assoc; 2020 Jun; 9(11):e016704. PubMed ID: 32468897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy.
    Zhao SX; Kwong C; Swaminathan A; Gohil A; Crawford MH
    JACC Heart Fail; 2018 Mar; 6(3):209-218. PubMed ID: 29496022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.
    Sutter ME; Gaedigk A; Albertson TE; Southard J; Owen KP; Mills LD; Diercks DB
    Clin Toxicol (Phila); 2013 Aug; 51(7):540-4. PubMed ID: 23855716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy.
    Osekowski M; Trytell A; La Gerche A; Prior D; MacIsaac A; Paratz ED
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):385-393. PubMed ID: 35157254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy.
    Schürer S; Klingel K; Sandri M; Majunke N; Besler C; Kandolf R; Lurz P; Luck M; Hertel P; Schuler G; Linke A; Mangner N
    JACC Heart Fail; 2017 Jun; 5(6):435-445. PubMed ID: 28571597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methamphetamine-associated cardiomyopathy.
    Won S; Hong RA; Shohet RV; Seto TB; Parikh NI
    Clin Cardiol; 2013 Dec; 36(12):737-42. PubMed ID: 24037954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methamphetamine-Associated Cardiomyopathy in Pregnancy: A Case Series.
    Pierce SL; Zantow EW; Phillips SD; Williams M
    Mayo Clin Proc; 2019 Mar; 94(3):551-554. PubMed ID: 30832798
    [No Abstract]   [Full Text] [Related]  

  • 10. Methamphetamine-Associated Congestive Heart Failure: Increasing Prevalence and Relationship of Clinical Outcomes to Continued Use or Abstinence.
    Sliman S; Waalen J; Shaw D
    Cardiovasc Toxicol; 2016 Oct; 16(4):381-9. PubMed ID: 26661075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Methamphetamine-associated Cardiomyopathy and the Impact of Methamphetamine Use on Cardiac Dysfunction.
    Reddy PK; Chau E; Patel SV; Yang K; Ng TM; Elkayam U
    Am J Cardiol; 2021 Sep; 154():86-91. PubMed ID: 34233837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methamphetamine addiction and medical futility.
    Mishra R
    Camb Q Healthc Ethics; 2013 Oct; 22(4):400. PubMed ID: 24229483
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand.
    Kueh SA; Gabriel RS; Lund M; Sutton T; Bradley J; Kerr AJ; Looi JL
    Heart Lung Circ; 2016 Nov; 25(11):1087-1093. PubMed ID: 27185546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse.
    Ito H; Yeo KK; Wijetunga M; Seto TB; Tay K; Schatz IJ
    Clin Cardiol; 2009 Jun; 32(6):E18-22. PubMed ID: 19330818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Too much heterogeneity: envisioning a new approach to methamphetamine associated heart failure.
    Davis JD
    Heart; 2023 Jan; 109(3):162-163. PubMed ID: 36456205
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Clinical Characteristics and Outcomes of Patients With Reversible Versus Persistent Methamphetamine-Associated Cardiomyopathy.
    Zhao SX; Seng S; Deluna A; Yu EC; Crawford MH
    Am J Cardiol; 2020 Jan; 125(1):127-134. PubMed ID: 31699360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methamphetamine-associated heart failure: a systematic review of observational studies.
    Manja V; Nrusimha A; Gao Y; Sheikh A; McGovern M; Heidenreich PA; Sandhu ATS; Asch S
    Heart; 2023 Jan; 109(3):168-177. PubMed ID: 36456204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Outcomes of Methamphetamine Abuse Among Veterans With Heart Failure.
    Nishimura M; Ma J; Fox S; Toomu A; Mojaver S; Juang DK; Maisel AS; Thomas IC
    Am J Cardiol; 2019 Sep; 124(6):907-911. PubMed ID: 31311659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine-Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities.
    Dickson SD; Thomas IC; Bhatia HS; Nishimura M; Mahmud E; Tu XM; Lin T; Adler E; Greenberg B; Alshawabkeh L
    J Am Heart Assoc; 2021 Aug; 10(16):e018370. PubMed ID: 34365802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor outcomes in methamphetamine-associated cardiomyopathy-a growing health issue in New Zealand.
    Wang TKM; Kueh SA; Sutton T; Gabriel R; Lund M; Looi JL
    N Z Med J; 2019 Sep; 132(1502):55-66. PubMed ID: 31563927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.